Entities / Company
Charles River Laboratories.
major US biomedical company
- Reports this week
- 1
- Active events
- 3
- Connections
- 87
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Agilent Technologies and Charles River Laboratories are both companies operating in the life sciences sector.Some support1 report1 development inside
-
Apollo is the digital client engagement platform for Charles River Laboratories, and Mark Mintz serves as CIO and head of global shared services.Some support1 report
-
Charles River Laboratories joined Eli Lilly’s TuneLab platform, while Trillium and LAL increased cartridge line capacity.Some support1 report
One to three months ago
-
Charles River Laboratories is involved with Invesco and State Street, holding significant shares and competing in the specialized healthcare ETF market.Some support2 reports
-
Weakened demand in the RMS segment due to factors in North America and flat spending from the National Institutes of Health.Some support1 report
-
UFP Technologies and Charles River Laboratories operate in the drug development inputs and services segment.Some support1 report
-
Market expansion in the pharmaceutical industry is being driven by growth.Some support1 report1 development inside
-
Charles River Laboratories is functioning as a critical outsourced research and drug development partner within the global pharmaceutical ecosystem.Some support1 report
Gone quiet
No new reports in 90+ days-
Morgan Stanley upgraded Charles River Laboratories stock to Overweight on June 22, 2026.Some support1 report
-
Morgan Stanley upgraded Charles River Laboratories and downgraded IQVIA Holdings on June 18th.Some support1 report
-
A BioPharma company located in Jílové u Prahy, Czech Republic, is transitioning its funding into RFPs and bookings.Some support1 report
-
A test highlighting value in personalized medicine is mentioned in a competitive market assessment involving Roche, Bio-Rad, and Charles River.Some support3 reports
-
Charles River uses CAP to support gene therapy development, a collaboration founded by Michelle and Dan Krueger.Some support1 report
-
Elliott Investment Management took a large stake in Charles River, a drugmaker, according to the Financial Times.Some support1 report
-
Charles River supports an EU-backed effort to improve access to CAR-T therapies in Europe.Some support1 report
-
Analysts probed DSA bookings strength and book-to-bill ratio amid stronger-than-expected demand in the segment.Speculative1 report
-
Todd Spencer was appointed Corporate Vice President of Investor Relations at Charles River Laboratories.Some support1 report
-
Charles River Laboratories is based in Wilmington, Massachusetts.Some support5 reports
-
Charles River Laboratories secured a contract to produce FibroBiologics' CYWC628 product as a Contract Development and Manufacturing Organization (CDMO).Some support1 report
-
James C. Foster leads Charles River Laboratories during a period of stabilization regarding biopharma demand.Some support2 reports
-
Charles River Laboratories received revenue contributions on August 11, 2025, from Canada ($135.59M), Brazil, and Israel.Some support1 report
-
Dole, Charles River Laboratories, and LegalZoom were analyzed as investment opportunities on August 15, 2025.Some support1 report
-
Fresenius Kabi, Charles River Laboratories, Intertek, and Gea were listed in a market report profile.Some support1 report
-
Palumbo joined Campbell's after serving at Charles River Laboratories and previously at Johnson & Johnson.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Charles River Laboratories this week
News at the entities that move Charles River Laboratories most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Charles River Laboratories
-
North America OperationalAn inaugural rodeo was held in Cape Breton, featuring athletes who represented North America.Moves Charles River Laboratories
-
Morgan Stanley OperationalFinancial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Moves Charles River Laboratories
-
Apollo StructuralThe company Apollo, General Motors, and the Big Bang event are linked to corporate bloat and risk management failures dating back to September 1, 2019.Moves Charles River Laboratories
-
National Institutes of Health StructuralPDS Biotechnology and the National Cancer Institute entered into a collaborative R&D agreement.Moves Charles River Laboratories
-
Trillium StructuralCarmen Rice manages sales for Trillium, a residential tower in Kamloops, while Fawcett represents the development.Moves Charles River Laboratories
Connections
The 18 strongest of 87, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Mark Mintz Structural
Mark Mintz serves as the Chief Information Officer and head of global shared services for Charles River Laboratories.
-
Eli Lilly and Company Structural
Charles River Laboratories is functionally integrated into the Eli Lilly TuneLab platform.
-
Apollo Structural
Apollo serves as the dedicated digital client engagement platform for Charles River Laboratories.
-
FDA Structural
The FDA regulates Charles River Laboratories' study designs and transition to New Approach Methodologies.
-
Morgan Stanley Operational
Morgan Stanley actively influences Charles River Laboratories' market valuation through investment recommendations and stock upgrades.
-
North America Operational
Weakened demand in North America directly impacts the operational segments of Charles River Laboratories.
-
National Institutes of Health Structural
NIH's operational spending patterns are cited as a contributing factor to the segment weakness of Charles River Laboratories.
-
Bio-Rad Laboratories Operational
Both companies are described as competitors occupying vital positions within the biotech supply chain.
Show all 18 connections
-
Trillium Structural
A is functionally integrated into B's operational capacity regarding Trillium product lines.
-
Invesco Structural
A holds a significant financial stake in B, establishing a formal investment link.
-
Agilent Technologies Shared context
Both companies operate within the life sciences sector.
-
UFP Technologies Shared context
Both companies operate as peers within the drug development inputs and services segment.
-
New York Shared context
Charles River Laboratories operates within the geographical context of New York.
-
Massachusetts Shared context
The company is geographically situated within the borders of the state of Massachusetts.
-
DSA Mentioned together
The evidence describes general business activity and demand within the DSA segment.
-
LAL Mentioned together
The evidence places both entities within the life sciences domain, noting LAL's internal capacity increases related to cartridge lines.
-
Vietnam Shared context
Charles River Laboratories operates and supports products within the regulatory market of Vietnam.
-
Bank of America Mentioned together
No direct coupling or interaction between Bank of America and Charles River Laboratories was observed in the provided evidence.
History
Events by the month they beganSeptember 2026
3 events- Agilent Technologies and Charles River Laboratories are both companies operating in the life sciences sector.
- Apollo is the digital client engagement platform for Charles River Laboratories, and Mark Mintz serves as CIO and head of global shared services.
- Charles River Laboratories joined Eli Lilly’s TuneLab platform, while Trillium and LAL increased cartridge line capacity.
August 2026
3 events- Charles River Laboratories is involved with Invesco and State Street, holding significant shares and competing in the specialized healthcare ETF market.
- Weakened demand in the RMS segment due to factors in North America and flat spending from the National Institutes of Health.
- UFP Technologies and Charles River Laboratories operate in the drug development inputs and services segment.
July 2026
1 eventShow 1 earlier month
June 2026
17 events- Market expansion in the pharmaceutical industry is being driven by growth.
- Morgan Stanley upgraded Charles River Laboratories stock to Overweight on June 22, 2026.
- Morgan Stanley upgraded Charles River Laboratories and downgraded IQVIA Holdings on June 18th.
- A BioPharma company located in Jílové u Prahy, Czech Republic, is transitioning its funding into RFPs and bookings.
- A test highlighting value in personalized medicine is mentioned in a competitive market assessment involving Roche, Bio-Rad, and Charles River.
- Charles River uses CAP to support gene therapy development, a collaboration founded by Michelle and Dan Krueger.
- Elliott Investment Management took a large stake in Charles River, a drugmaker, according to the Financial Times.
- Charles River supports an EU-backed effort to improve access to CAR-T therapies in Europe.
- Analysts probed DSA bookings strength and book-to-bill ratio amid stronger-than-expected demand in the segment.
- Todd Spencer was appointed Corporate Vice President of Investor Relations at Charles River Laboratories.
- Charles River Laboratories is based in Wilmington, Massachusetts.
- Charles River Laboratories secured a contract to produce FibroBiologics' CYWC628 product as a Contract Development and Manufacturing Organization (CDMO).
- James C. Foster leads Charles River Laboratories during a period of stabilization regarding biopharma demand.
- Charles River Laboratories received revenue contributions on August 11, 2025, from Canada ($135.59M), Brazil, and Israel.
- Dole, Charles River Laboratories, and LegalZoom were analyzed as investment opportunities on August 15, 2025.
- Fresenius Kabi, Charles River Laboratories, Intertek, and Gea were listed in a market report profile.
- Palumbo joined Campbell's after serving at Charles River Laboratories and previously at Johnson & Johnson.